Tau: From research to clinical development

[1]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[2]  E. Mandelkow,et al.  Tau neurotoxicity and rescue in animal models of human Tauopathies , 2016, Current Opinion in Neurobiology.

[3]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[4]  A. Goldberg,et al.  Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling , 2015, Nature Medicine.

[5]  Anirvan Ghosh,et al.  Specification of synaptic connectivity by cell surface interactions , 2015, Nature Reviews Neuroscience.

[6]  E. Mandelkow,et al.  Tau in physiology and pathology , 2015, Nature Reviews Neuroscience.

[7]  Jennifer Luebke,et al.  Depletion of microglia and inhibition of exosome synthesis halt tau propagation , 2015, Nature Neuroscience.

[8]  Meaghan Morris,et al.  Tau post-translational modifications in wildtype and human amyloid precursor protein transgenic mice , 2015, Nature Neuroscience.

[9]  R. Bateman,et al.  In vivo kinetic approach reveals slow SOD1 turnover in the CNS. , 2015, The Journal of clinical investigation.

[10]  E. Sigurdsson,et al.  Tau immunotherapy for Alzheimer's disease. , 2015, Trends in molecular medicine.

[11]  J. Trojanowski,et al.  Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models , 2015, PloS one.

[12]  B. Hyman,et al.  Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease , 2015, Acta neuropathologica communications.

[13]  H. Braak,et al.  PART is part of Alzheimer disease , 2015, Acta Neuropathologica.

[14]  J. Götz,et al.  Tau aggregation and its interplay with amyloid-β , 2014, Acta Neuropathologica.

[15]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[16]  C. Gong,et al.  Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice , 2014, Molecular Neurodegeneration.

[17]  D. Vocadlo,et al.  The Emerging Link between O-GlcNAc and Alzheimer Disease* , 2014, The Journal of Biological Chemistry.

[18]  W. Oertel,et al.  Tau silencing by siRNA in the P301S mouse model of tauopathy. , 2014, Current gene therapy.

[19]  N. Krogan,et al.  Critical Role of Acetylation in Tau-Mediated Neurodegeneration and Cognitive Deficits , 2015, Nature Medicine.

[20]  J. Haines,et al.  Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain gene expression levels , 2014, Alzheimer's Research & Therapy.

[21]  L. McIntosh,et al.  O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers. , 2014, Journal of molecular biology.

[22]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[23]  A. Fagan,et al.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study , 2013, The Lancet Neurology.

[24]  Michel Goedert,et al.  Tau pathology and neurodegeneration , 2013, The Lancet Neurology.

[25]  Sarah L. DeVos,et al.  Antisense Oligonucleotides: Treating Neurodegeneration at the Level of RNA , 2013, Neurotherapeutics.

[26]  E. Mandelkow,et al.  Cascade of tau toxicity in inducible hippocampal brain slices and prevention by aggregation inhibitors , 2013, Neurobiology of Aging.

[27]  S. Younkin,et al.  Tau Loss Attenuates Neuronal Network Hyperexcitability in Mouse and Drosophila Genetic Models of Epilepsy , 2013, The Journal of Neuroscience.

[28]  Matthew S Macauley,et al.  Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. , 2012, Nature chemical biology.

[29]  D. Holtzman,et al.  Trans-cellular Propagation of Tau Aggregation by Fibrillar Species* , 2012, The Journal of Biological Chemistry.

[30]  Hans-Ulrich Demuth,et al.  Prion-Like Behavior and Tau-dependent Cytotoxicity of Pyroglutamylated β-Amyloid , 2012, Nature.

[31]  Naruhiko Sahara,et al.  Propagation of Tau Pathology in a Model of Early Alzheimer's Disease , 2012, Neuron.

[32]  D. Dickson,et al.  Immunoelectron Microscopic and Biochemical Studies of Caspase-Cleaved Tau in a Mouse Model of Tauopathy , 2011, Journal of neuropathology and experimental neurology.

[33]  Jason T. Stevens,et al.  Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation , 2011, Nature.

[34]  Andrew J. Lees,et al.  Identification of common variants influencing risk of the tauopathy Progressive Supranuclear Palsy , 2011, Nature Genetics.

[35]  Meaghan Morris,et al.  The Many Faces of Tau , 2011, Neuron.

[36]  Rudi D'Hooge,et al.  Tau-Induced Defects in Synaptic Plasticity, Learning, and Memory Are Reversible in Transgenic Mice after Switching Off the Toxic Tau Mutant , 2011, The Journal of Neuroscience.

[37]  M. Farrer,et al.  MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy , 2011, Neurology.

[38]  E. Yaksi,et al.  Electrical Coupling between Olfactory Glomeruli , 2010, Neuron.

[39]  E. Yaksi,et al.  Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy , 2010, Neuron.

[40]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[41]  Min Jae Lee,et al.  Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of Usp14 , 2010, Nature.

[42]  B. Hyman,et al.  Caspase activation precedes and leads to tangles , 2010, Nature.

[43]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[44]  J. Trojanowski,et al.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.

[45]  Martin Beibel,et al.  Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.

[46]  R. Wade-Martins,et al.  Knock-out and transgenic mouse models of tauopathies , 2009, Neurobiology of Aging.

[47]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[48]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[49]  A J Lees,et al.  Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration , 2005, Journal of Medical Genetics.

[50]  H. Stefánsson,et al.  A common inversion under selection in Europeans , 2005, Nature Genetics.

[51]  John Q Trojanowski,et al.  Transgenic animal models of tauopathies. , 2005, Biochimica et biophysica acta.

[52]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[53]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[55]  G. Schellenberg,et al.  Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.

[56]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[57]  B. Hyman,et al.  The Natural History of Alzheimer Neurofibrillary Tangles and Amyloid Deposits , 1997, Neurobiology of Aging.

[58]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[59]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[60]  H. Wiśniewski,et al.  Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. , 1986, The Journal of biological chemistry.

[61]  J. Kramer,et al.  Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. , 2014, Annals of neurology.

[62]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[63]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.

[64]  Brian J. Wiltgen,et al.  Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-b , 2012 .

[65]  C. Cella,et al.  Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011 .

[66]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[67]  Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products , 1998 .